MBOT - הכנסה תפעולית לפני ניכוי פחת Microbot Medical

Cost optimization through outsourced manufacturing while maintaining control over R&D ensures the stability of Microbot Medical Inc. (MBOT). The EBITDA on this GURU.Markets platform chart reflects current dynamics, where the latest parameter stands at 0.00. This supports the expansion of the Liberty system in the US and strengthens the brand's status as an innovator in the field of safe microrobotic surgery.

This indicator captures actual cash flow from operating activities before accounting adjustments, allowing investors to assess the business's real ability to generate cash outside of GAAP frameworks. By analyzing the EBITDA history, one can compare capitalization rates with FDA certification costs and the implementation of robotic systems at Microbot Medical Inc. (MBOT), which determines the asset's fundamental stability within the high-tech sector.